Prasugrel

Catalog No.S1258 Synonyms: CS-747, LY640315

For research use only.

Prasugrel (CS-747, LY640315) is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.

Prasugrel Chemical Structure

CAS No. 150322-43-3

Selleck's Prasugrel has been cited by 2 Publications

Purity & Quality Control

Choose Selective P2 Receptor Inhibitors

Other P2 Receptor Products

Biological Activity

Description Prasugrel (CS-747, LY640315) is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.
Targets
P2Y12 receptor [1]
In vitro

Prasugrel is a novel orally active thienopyridine with faster, higher and more reliable inhibition of platelet aggregation than clopidogrel reflecting its metabolism in vivo to an active metabolite with selective P2Y(12) antagonistic activity. [1]

Assay
Methods Test Index PMID
Western blot p-VEGDFR2 / VEGFR2 / p-STAT3 / STAT3 / p-p65 / p65 / p-AKT / AKT / p-ERK / ERK 28383032
In vivo Prasugrel shows platelet inhibition that was 8.2 times more potent than clopidogrel in WT mice. [1] Prasugrel (3 and 10 mg/kg) dose-relatedly and significantly reduces thrombus-mediated cerebral infarction 24 hours after the irradiation in rat models of cerebral and peripheral arterial occlusive diseases. Prasugrel (0.3-3 mg/kg) reduces incidence, total area, and total number of cerebral infarcts in a dose-related manner 24 hours after the vascular injury in an embolic infarction rats model. Prasugrel (0.03-3 mg/kg/day) administered from the day before the lauric acid injection for 11 successive days inhibits the progression of the disease in a dose-related manner in rats with lauric acid-induced peripheral arterial occlusive diseases. [2] Prasugrel administrated in dogs (0.03-0.3 mg/kg/day) and monkeys (0.1 and 0.3 mg/kg/day) once a day for 14 days results in potent, dose-related and cumulative inhibition of ADP-induced platelet aggregation. Prasugrel (0.1-1 mg/kg/day, p.o.) significantly prolongs the time to arterial occlusion and increases the duration of arterial patency in a rat model of electrically-induced arterial thrombosis. [3]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 373.44
Formula

C20H20FNO3S

CAS No. 150322-43-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05053828 Enrolling by invitation Drug: Antiplatelet Drug Type2 Diabetes|Antiplatelet Drugs|Myocardial Infarction|Heart Failure Tabula Rasa HealthCare September 20 2021 --
NCT04471870 Active not recruiting -- Acute Coronary Syndrome Chiesi Farmaceutici S.p.A. October 23 2020 --
NCT02302508 Withdrawn Drug: Clopidogrel Prasugrel Ticagrelor Diabetes Centre hospitalier de l''Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l''Université de Montréal September 1 2019 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Prasugrel | Prasugrel supplier | purchase Prasugrel | Prasugrel cost | Prasugrel manufacturer | order Prasugrel | Prasugrel distributor